Pictet Asset Management
IOVA icon

Pictet Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Pictet Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Hold
43,048
– – ﹤0.01% 2025
2026
Q1 		$151K Buy
43,048
+15,926
+59% +$50.9K ﹤0.01% 1986
2025
Q4 		$74K Hold
27,122
– – ﹤0.01% 2050
2025
Q3 		$58.9K Hold
27,122
– – ﹤0.01% 2019
2025
Q2 		$46.6K Sell
27,122
-893,339
-97% -$2.22M ﹤0.01% 1989
2025
Q1 		$3.27M Buy
920,461
+89,402
+11% +$461K ﹤0.01% 849
2024
Q4 		$6.15M Sell
831,059
-71,209
-8% -$660K 0.01% 773
2024
Q3 		$8.66M Sell
902,268
-17,809
-2% -$169K 0.01% 691
2024
Q2 		$7.38M Sell
920,077
-2,330,477
-72% -$25M 0.01% 704
2024
Q1 		$47.5M Sell
3,250,554
-2,012,755
-38% -$23.4M 0.05% 319
2023
Q4 		$42.8M Sell
5,263,309
-1,650,375
-24% -$8.64M 0.05% 339
2023
Q3 		$31.5M Buy
+6,913,684
New +$45.1M 0.04% 359

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Pictet Asset Management's IOVA Position: Q2 2026 in Review

Pictet Asset Management held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 43,048 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #2025.

Pictet Asset Management first reported a position in IOVA in Q3 2023 and has held it in 12 quarters since. The position peaked at $47.5M in Q1 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Pictet Asset Management held 43,048 shares of Iovance Biotherapeutics worth $179K as of Q2 2026.
  • Pictet Asset Management left its Iovance Biotherapeutics share count unchanged in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #2025 holding.
  • Pictet Asset Management first reported a position in Iovance Biotherapeutics in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Iovance Biotherapeutics position peaked at $47.5M in Q1 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.